Jin10 data reported on August 19, Beida Pharmaceutical stated on the interactive platform that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will disclose any significant research progress in a timely manner.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BeiGene: MCLA-129 is currently exploring indications in the field of lung cancer.
Jin10 data reported on August 19, Beida Pharmaceutical stated on the interactive platform that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will disclose any significant research progress in a timely manner.